Psychiatric Issues in Vitiligo

Psychocutaneous Medicine

Volumn , Issue , 2003, Pages 351-363

  Lee, Ernest ^a   Koo, John Y M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42349105837     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203911877-26     Document Type: Chapter

References (64)

1. Fitzpatrick T, Szabo G. The melanocyte: cytology and cytochemistry. J Invest Dermatol 1959;32:197-209.
2. Tsatmali M, Ancans J, Thody AJ. Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem 2002;50:125-133.
3. Sams WM. Structure and Function of the Skin. In Sams WM, Lynch PJ, eds. Principles and Practice of Dermatology. 2nd ed. Churchill Livingstone Inc., 1996, New York.
4. Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom 2001;70(3):118-136.
5. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-666.
6. Nordlund JJ, Lerner AB. Vitiligo: it is important. Arch Dermatol 1982;118:5-8.
7. Agarwal G. Vitiligo: an under-estimated problem. Fam Pract 1998; 15:S19-23.
8. Griesemer RD. Emotionally triggered disease in a dermatological practice. Psychiatr Ann 1978; 8:49-56.
9. Papadopoulos L, Bor R, Legg C, et al. Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol 1998; 23:243-248.
10. Naughton G, Eisinger M, Bystryn J. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158:246-251.
11. Naughton G, Eisinger M, Bystryn J. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81:540-542.
12. Naughton G, Reggiardo D, Bystryn J. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15:978-981.
13. Lerner A. On the etiology of vitiligo and gray hair. Am J Med 1971; 51:141-147.
14. Lerner A. Vitiligo. J Invest Dermatol 1959; 32:285-310.
15. Drolet G, Dumont EC, Gosselin I, et al. Role of endogenous opioid system in the regulation of the stress response. Prog Neuro-Psychopharmacol Biol Psychiatry 2001; 25:729-741.
16. Dantzer R, Kelley KW. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci 1989; 44:1995-2008.
17. Khansari DN, Murgo AJ, Faith RE. Effect of stress on the immune system (review). Immunol Today 1990; 11:170-175.
18. Schlesinger M, Yodfat Y. Effect of psychosocial stress and natural killer cell activity. Cancer Detect Prev 1988; 12:9-14.
19. Herberman RB, Djeu J, Kay HD, et al. Natural killer cells: characteristics and regulation of activity. Immunol Rev 1979; 44:43-70.
20. Mozzanica N, Villa M, Foppa S, et al. Plasma a-melanocyte-simulating hormone, b-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992; 26:693-700.
21. Durham-Pierre DG, Walters CS, Halder RM, et al. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995; 33:26-30.
22. Lindley SE, Lookingland KJ, Moore KE. Dopaminergic and beta-adrenergic receptor control of alpha-melanocyte stimulating hormone secretion during stress. Neuroendocrinology 1990; 52:46-51.
23. Slavnov VN, Luchitski EV, Oleinik VA, et al. The secretion of alphamelanotrophin in disease of the hypothalamas-hypophysis adrenal cortex system. Probl Endokrinol (Mosk) 1990; 36:40-43. (In Russian, abstract in English.)
24. Cannon JG, Tatro JB, Reichlin S, et al. Alpha-melanocyte stimulating hormone inhibits immunostimulatory and inflammatory actions of interleukin-1. J Immunol 1986; 137:2232-2238.
25. Katsambas AD, Schulpis KH, Antoniou C, et al. Beta endorphin serum levels in patients with vitiligo. J Eur Acad Dermatol Venereol 1994; 3:22-26.
26. Tu C-X, Zhao D-M, Lin X-R. Levels of b-endorphin in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001; 26:62-66.
27. Pawelek J, Korner A, Bergstrom A, et al. New regulators of melanin biosynthesis and the autodestruction of melanoma cells. Nature 1980; 286:617-619.
28. Shavit Y, Lewis J, Terman G, et al. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxiciy. Science 1984; 223:188-193.
29. Plotnikoff N, Good RA, Faith RE, Murgo AJ. Enkephalins and Endorphins: Stress and the Immune System. New York: Plenum Press, 1986.
30. Jeijnen CJ, Zijlstra J, Kavelaars A, et al. Modulation of the immune response by POMC-derived peptides. Brain Behav Immun 1987; 1:284-291.
31. Kay N, Allen J, Morley JE. Endorphins stimulate normal human peripheral blood lymphocyte natural killer activity. Life Sci 1984; 35:53-59.
32. Baram D, Simantov R. Enkephalins and opiate antagonists control calmodulin distribution in neuroblastoma-glioma cells. J Neurochem 1983; 40:55-63.
33. Cucchi ML, Frattini P, Santagostino G, Orecchia G. Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res 2000; 13:28-32.
34. Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 1995; 190:109-115.
35. Schallreuter KU, Wood JM, Pittelkow MR, Steinkraus V. High expression of beta-2 adrenoreceptors in vitiligo. Arch Dermatol Res 1993; 285:215-220.
36. Shelley WB, Ohman S. Epinephrine induction of white hair in AC1-rats. J Invest Dermatol 1969; 53:155-158.
37. Morrone A, Picardo M, DeLuca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5:65-69.
38. LePoole C, Das KP. Microscopic changes in vitiligo. Clin Dermatol 1997; 15:863-873.
39. Slominski A, Paus R, Bormiski A. Hypothesis: possible role for the melatonin receptor in vitiligo: discussion paper. J Roy Soc Med 1989; 82:539-541.
40. Fabbri P. Immunodermatologia. Brescia: ISED, 1993:337-363.
41. Halaban R, Langdon R, Birchall N. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988; 107:1611-1619.
42. Lakin ML, Miller CH, Stott Ml, et al. Involvement of the pineal gland and melatonin in murine analgesia. Life Sci 1981; 19:2543-2547.
43. Lissoni P, Esposti D, Esposti G, et al. A clinical study on the relationship between the pineal gland and the opioid system. J Neural Trans 1986; 65:63-73.
44. Maestroni GJM, Conti A. b-Endorphin and dynorphin mimic the circadian immunoenhancing and antistress effects of melatonin. Int J Immunopharmacol 1989; 11:333-340.
45. Le Poole C, Das PK, van der Wijngaard RM, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2:145-153.
46. Porter JR, Beuf AH, Lerner AB, et al. The effect of vitiligo on sexual relationships. J Am Acad Dermatol 1990; 22:221-222.
47. Kent G, Al’ Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 1996; 35:895-898.
48. Porter JR, Beuf AH, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with ‘‘normal’’ control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol 1986; 15:220-224.
49. Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: a comparative study. J Dermatol 2001; 28(8):419-423.
50. Matto SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: a comparative study from India. J Dermatol 2001; 28:424-432.
51. Porter J, Beuf A, Nordlund J, et al. Psychological reaction to chronic skin disorders. Gen Hosp Psych 1979; 1:73-77.
52. Dion K, Bersheid E, Walster E. What is beautiful is good. J Pers Soc Psychol 1972; 24:215-220.
53. Siller J, Ferguson L, Vann D, Holland B. Structure of attitudes toward the physically disabled: the disability factor scale: amputation, blindness, cosmetic conditions. Proceedings of 76th Annual Convention of American Psychological Association, San Francisco, 1968, pp. 651-652.
54. Piliavin IM, Piliavin JA, Rodin J. Costs, diffusion, and the stigmatized victim. J Pers Soc Psychol 1975; 32:429-438.
55. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42:245-253.
56. Gomez-Bezares P, Vazquez-Doval FJ. Neuropeptides in dermatologic therapy. Rev Neurol 1997; 25(3):S320-324.
57. Konicki PE, Schulz SC. Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior. Psychopharmacol Bull 1989; 25:556-563.
58. Mason PJ. Vitiligo: the psychosocial effects. Medsurg Nurs 1997; 6:216-218.
59. Winchell S, Watts R. Relaxation therapies in the treatment of psoriasis and possible pathophysiological mechanisms. J Am Acad Dermatol 1988; 18:101-104.
60. Price M, Mottahedin I, Mayo P. Can psychotherapy help patients with psoriasis? Clin Exp Dermatol 1991; 16:114-117.
61. Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioral therapy. Br J Med Psychol 1999; 72:385-396.
62. Scott MJ. Hypnosis in Skin and Allergic Diseases. Springfield, IL: Charles C Thomas, 1960.
63. Tobia L. L’ipnosi in dermatologia. Minerva Med. 1982; 73:531-537.
64. Patridge J. Changing Faces. The Challenge of Facial Disfigurement. London: Changing Faces, 1994.